1Raab O. Infusuria Zeitschrift Biologic 1990 524～546
2Liu H, etal. DermatolClin 1993 11:1-13
3Dougherty TJ, et al. J Nat Cancer Inst 1975 55: 115-121
4Dougherty TJ, et al. Eur J Cancer 1992 28A: 1734-1742
5Foote CS. In: Dorion DR, Gomer CJ, eds. Porphyrin Localization the Treatment of Tumors. Newyork, NY: Alan R Liss 1984 3～18
6BuettnerGR, etal. FEBSLett 1980 121:161-164
7Weishaupt KR, et al. Cancer Res 1976 36:2326-2329
8Dougherty TJ, et al. J Natl Cancer Inst 1998 90:889-905
9Hilf R Smail DB, et al. Cancer Res 1984 44:1483-1488
10Specht KG, et al. Photochem photobiol 1990 51:319-324
同被引文献11
1Rogers AH, Martidis A, Greenberg PB, et al. Optical coherence tomography findings following photodynamie therapy of choroidal neovascularization. Am J Ophthahnol,2002,134:566-576.
2Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group. Photodynamic therapy of subfoveral choroidal neovascularization in age-related macular degeneration with verteporfin. Arch Ophthalmol, 1999,117 : 1329-1330.
3Ciulla TA, Danis RP, Harris A. Age-related macular degeneration : a review of experimental treatments. Sarv Ophthalmol, 1998,43: 134-136.
4Gilaberte Y, Pereboom D, Carapeto FJ, et al. Flow cytometry study of the role of superoxide anion and hydrogen peroxide in cellular photodestruction with 5-aminolevulinie acid-induced protoporphyrin Ⅸ. Photodermatol Photoimmunol Photomed, 1997,13:43-49.
5Treatment of age-related macular degeneration with photodynamic therapy study group and verteporfin in photodynamic therapy study group. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration:TAP and VIP report No. 1. Am J Ophthalmol,2003, 136:407-418.
6Treatment of age-related maeular degeneration with photodynamie therapy (TAP) study group. Verteporfin therapy of subfoveral choroidal neovascularization in age-related macular degeneration, two-year results of a randomized clinical trial including lesions with occult with no classical choroidal neovascularization:verteporfin in photodynamic therapy report. Am J Ophthalmol,2001,131 : 541- 560.
7Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group and verteporfin in photodynamic therapy (VIP) study group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: mtea-analysis of 2-year safety results in three randomized clinical trials, treatment of age-related macular degeneration with photodynamic therapy and verteporfin in photodynamic therapy study report No. 4. Retina ,2004,24:1-12.
